Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Open access
Tu, Megan M., Abdel-Hafiz, Hany A., Jones, Robert T., Jean, Annie, Hoff, Katelyn J., Duex, Jason E., Chauca-Diaz, Ana, Costello, James C., Dancik, Garrett M., Tamburini, Beth A. Jirón, Czerniak, Bogdan, Kaye, Jonathan, Theodorescu, Dan · 2020 · Communications Biology

Abstract

Immunotherapies targeting the PD-1/PD-L1 axis are now a mainstay in the clinical management of multiple cancer types, however, many tumors still fail to respond. CCL2 is highly expressed in various cancer types and has been shown to be associated with poor prognosis. Inhibition or blockade of the CCL2/CCR2 signaling axis has thus been an area of interest for cancer therapy. Here we show across multiple murine tumor and metastasis models that CCR2 antagonism in combination with anti-PD-1 therapy leads to sensitization and enhanced tumor response over anti-PD-1 monotherapy. We show that enhanced treatment response correlates with enhanced CD8+ T cell recruitment and activation and a concomitant decrease in CD4+ regulatory T cell. These results provide strong preclinical rationale for further clinical exploration of combining CCR2 antagonism with PD-1/PD-L1-directed immunotherapies across multiple tumor types especially given the availability of small molecule CCR2 inhibitors and antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-020-01441-y

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 178

Metadata

Authors
Tu, M. M., Abdel-Hafiz, H. A., Jones, R. T., Jean, A., Hoff, K. J., Duex, J. E., Chauca-Diaz, A., Costello, J. C., Dancik, G. M., Tamburini, B. A. J., Czerniak, B., Kaye, J., & Theodorescu, D.
Venue
Communications Biology
Published
2020-11-27
Volume
3
Issue
1
Pages
720-720
ISSN
2399-3642 (ISSN-L)
OpenAlex
W3109702162
Cited by
178
References
17
FWCI
6.50
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. https://app.cochat.ai/papers/10.1038/s42003-020-01441-y
The paper
Tu, M. M., Abdel-Hafiz, H. A., Jones, R. T., Jean, A., Hoff, K. J., Duex, J. E., Chauca-Diaz, A., Costello, J. C., Dancik, G. M., Tamburini, B. A. J., Czerniak, B., Kaye, J., & Theodorescu, D. (2020). Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Communications Biology. https://doi.org/10.1038/s42003-020-01441-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.